The HTRA2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the HTRA2 gene has been disrupted in the human A-549 lung adenocarcinoma epithelial cell line. This product provides a pooled loss-of-function model without clonal isolation, maintaining population-level heterogeneity while achieving robust target-gene disruption. The polyclonal format ensures a broadly representative knockout background, enabling physiologically relevant investigations of HTRA2-dependent processes across a mixed cellular context.
A-549 cells were originally derived from the lung carcinoma tissue of a 58-year-old Caucasian male and exhibit characteristic epithelial morphology. As an alveolar basal epithelial model, this line is extensively employed in respiratory disease research and oncology, offering a stable and well-characterized platform for genetic modification. Its adherent growth, reproducible responses to perturbagens, and defined signaling networks make A-549 cells an ideal host for CRISPR-mediated functional genomics studies, particularly those examining apoptosis, stress responses, and mitochondrial biology.
HTRA2 encodes a mitochondrial serine protease with dual roles in apoptosis regulation and mitochondrial protein quality control. Under apoptotic stimuli, mitochondrial membrane depolarization and reactive oxygen species trigger HTRA2 release into the cytosol, where it cleaves inhibitor of apoptosis proteins including XIAP, cIAP1, and cIAP2, thereby relieving caspase inhibition and promoting cell death. In basal conditions, HTRA2 operates within the PINK1/Parkin pathway, regulated by PINK1 kinase and PARL protease, to degrade misfolded mitochondrial proteins and preserve organelle integrity. The protein interacts with HAX1 and is functionally linked to key components of the intrinsic apoptosis pathway, such as cytochrome c, SMAC/DIABLO, BAX, and BCL-2.
The combination of HTRA2 knockout and the A-549 lung adenocarcinoma background yields a powerful model for deciphering the interplay between mitochondrial quality control and apoptotic signaling in a cancer-relevant setting. Loss of HTRA2 in these cells allows interrogation of how mitochondrial stress pathways influence sensitivity to chemotherapeutic agents and targeted therapies. This model is particularly valuable for exploring mechanisms of drug resistance, as HTRA2-mediated proteostasis may contribute to cell survival decisions. Additionally, it provides a non-neuronal platform to study Parkinson’s disease-related pathways, given HTRA2’s role in neurodegenerative processes through impaired mitochondrial function.
Research applications for these polyclonal knockout cells include detailed apoptosis studies using caspase-3/7 activity assays, cytochrome c release quantification, and flow cytometry with Annexin V/PI staining. Mitochondrial function can be assessed via JC-1 membrane potential measurements and stress tests with FCCP or oligomycin. The cells support Western blotting for HTRA2 and its substrates, co-immunoprecipitation to analyze protein interactions, and qRT-PCR for downstream effector genes. They are well-suited for drug screening campaigns targeting IAP antagonists and for validating modulators of the PINK1/Parkin axis. For further information or to discuss custom gene editing needs, please contact Ascent Research.
